EMA Decides Fast-Track Fate Of Masitinib And Anthrax Antitoxin

 
• By Neena Brizmohun
  
Bacteria
Anthrax antitoxin developer Elusys is one of two new companies seeking an accelerated assessment • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Product Reviews

More from Pink Sheet